Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming.
Henry F Frierson1, Christopher A Moskaluk
1University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA. hff@virginia.edu
The Journal of Clinical Investigation
|June 20, 2013
Related Experiment Videos
View abstract on PubMed
Summary
This study reveals that adenoid cystic carcinoma (ACC) is driven by alterations in chromatin regulatory genes and specific transcriptional regulators, rather than common oncogenes. These genetic changes are key to understanding ACC development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Adenoid cystic carcinoma (ACC) is a rare cancer, typically originating in salivary glands.
- A hallmark of ACC is the MYB-NFIB gene fusion, which enhances MYB transcriptional activity.
Purpose of the Study:
- To conduct comprehensive genomic mutation profiling of adenoid cystic carcinoma.
- To identify key genetic alterations driving ACC pathogenesis.
Main Methods:
- Genomic mutation profiling analysis of ACC.
- Analysis of gene fusions and mutations, including SPEN.
Main Results:
- Identified common alterations in chromatin regulatory genes in ACC.
- Discovered mutations in SPEN, an RNA-binding protein, suggesting roles in NOTCH, FGFR, and other signaling pathways.
- Observed a low prevalence of mutations in typical oncogenes and tumor-suppressor genes.
Conclusions:
- The development of ACC is primarily driven by specific transcriptional regulatory gene alterations and chromatin structure changes.
- These specific genetic drivers, rather than mutations in common oncogenes, are central to ACC's neoplastic process.